416 related articles for article (PubMed ID: 33176832)
1. Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).
Bayram F; Sonmez A; Haymana C; Sabuncu T; Dizdar OS; Gurkan E; Carlioglu AK; Agbaht K; Ozdemir D; Demirci I; Barcin C; Salman S; Tetiker T; Balci MK; Kebapci N; Ersoy C; Yumuk V; Toth PP; Satman I;
Lipids Health Dis; 2020 Nov; 19(1):237. PubMed ID: 33176832
[TBL] [Abstract][Full Text] [Related]
2. The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey.
Kahya Eren N; Harman E; Dolek D; Emren S; Tütüncüoğlu AP; Nazli C; Ergene O
Minerva Cardioangiol; 2014 Jun; 62(3):287-95. PubMed ID: 24831765
[TBL] [Abstract][Full Text] [Related]
3. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHESUS registry.
Mert KU; Başaran Ö; Mert GÖ; Doğan V; Rencüzoğulları İ; Özlek B; Cinier G; Şenol U; Çelik O; Özlek E; Özdemir İH; Karadeniz FÖ; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Akay K; Pekel N; Biteker M; Kayıkçıoğlu M
Eur J Clin Invest; 2021 Jul; 51(7):e13528. PubMed ID: 33630348
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
5. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study.
Selim S; Alam MS; Talukder SK; Kabir ML; Gaffar AJ; Kabir MA; Zarin N; Rahman S; Nabi MMU; Mustari M; Hossain MF; Raunak AIB; Hoque MA; Islam MR; Akter F; Hannan MA; Saifuddin M; Asaduzzaman M; Rahman MM; Ahammed A; Rafi MA; Hasan MJ; Kamrul-Hasan ABM
BMC Endocr Disord; 2023 Dec; 23(1):268. PubMed ID: 38053073
[TBL] [Abstract][Full Text] [Related]
8. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
11. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
12. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
13. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
14. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
Jones PH; Nair R; Thakker KM
J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
[TBL] [Abstract][Full Text] [Related]
17. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
[TBL] [Abstract][Full Text] [Related]
18. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II
Hermans MP; Gevaert S; Descamps O; Missault L; Gillot B; De Keyzer D; Lautsch D; Brudi P; Ambegaonkar B; Vyas A; Horack M; Gitt A
Acta Clin Belg; 2019 Dec; 74(6):399-404. PubMed ID: 30355016
[No Abstract] [Full Text] [Related]
19. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
